Evaluation of Antiemetic Therapy for Hepatic Transcatheter Arterial Infusion Chemotherapy with Cisplatin

• Published in: Biological & pharmaceutical bulletin Vol. 39; no. 4; pp. 611 - 614
• Main Authors: Hashizume, Junya, Higuchi, Norihide, Sato, Kayoko, Kodama, Yukinobu, Matsunaga, Noriko, Sakamoto, Toshiaki, Yamaguchi, Kentaro, Nakamura, Tadahiro, Kitahara, Takashi, Sasaki, Hitoshi
• Format: Journal Article
• Language: English
• Published: Japan The Pharmaceutical Society of Japan 01.04.2016; Japan Science and Technology Agency
• Subjects: 5-hydroxytryptamine3 (5-HT3) receptor antagonist; Adult; Aged; Aged, 80 and over; antiemetic; Antiemetics - therapeutic use; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Bridged Bicyclo Compounds, Heterocyclic - therapeutic use; Catheterization, Peripheral; cisplatin; Cisplatin - administration & dosage; Cisplatin - adverse effects; Cisplatin - therapeutic use; Dexamethasone - therapeutic use; Drug Therapy, Combination; Female; Granisetron - therapeutic use; Humans; Isoquinolines - therapeutic use; Liver; Liver Neoplasms - drug therapy; Male; Middle Aged; Morpholines - therapeutic use; Nausea - chemically induced; Nausea - prevention & control; Oxazines - therapeutic use; Quinuclidines - therapeutic use; Serotonin 5-HT3 Receptor Antagonists - therapeutic use; transcatheter infusion chemotherapy; Vomiting - chemically induced; Vomiting - prevention & control
• ISSN: 0918-6158; 1347-5215
• DOI: 10.1248/bpb.b15-00603

Antiemetic prophylaxis with aprepitant, a 5-hydroxytryptamine3 (5-HT3) receptor antagonist and dexamethasone is recommended for patients receiving intravenous cisplatin chemotherapy. Whether the same antiemetic regime is superior for hepatic transcatheter arterial infusion chemotherapy with cisplatin (CDDP-TAI) is unknown. We conducted a retrospective study of antiemetic prophylaxis protection against chemotherapy-induced nausea and vomiting (CINV) in CDDP-TAI at Nagasaki University Hospital. The rate of complete response (CR) to antiemetics in the acute (<24 h) and delayed phases (24–120 h) was measured. Twenty-four patients were treated with a 5-HT3 receptor antagonist (granisetron or azasetron) and dexamethasone on the day of chemotherapy (day 1 only). There was a significant difference between the CR rates in the acute and delayed phases, 91.6, and 69.7%, respectively. Combination of a 5-HT3 antagonist and dexamethasone on day 1 is effective against acute CINV, but not delayed CINV during CDDP-TAI. These results may help guide the management of nausea and vomiting during CDDP-TAI to achieve better tolerance and compliance for fewer interventions and increased favorable therapeutic outcomes.